Bolt Biotherapeutics

Share on: 

Bolt Biotherapeutics develops the  Boltbody™ platform, which consists of systemically delivered Immune-Stimulating Antibody Conjugates (ISAC). They conjugate tumor-targeting antibodies to powerful immune stimulants such as TLR agonists, proven to convert cold tumors into immunologically hot tumors, and have demonstrated that Boltbody™ ISACs eliminate tumors in preclinical models following systemic administration.

Career Page(s): 
Redwood CA
United States